IL17A and uveitis: Given the emerging data supporting a key role for IL-17 in patients with AS and related spondyloarthropathies [22,23], we tested whether systemically administered blocking antibody to IL-17 would alter the onset and/or severity of uveitis occurring in the absence of IFNγ.